Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820885 · ClinicalTrials.gov registry record · Phase 1
A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT00820885 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 95 participants.
The verdict
NCT00820885, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The primary objective of the study was to study the safety and tolerability of teduglutide following a once or possibly twice daily subcutaneous injection for eight consecutive days in healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide following a once or possibly twice daily injection for eight consecutive days in healthy subjects.
Interventions
- DRUG teduglutide
- DRUG tedguglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2006-09-06 |
| Est. Completion | 2007-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820885
The ClinicalTrials.gov registry entry for NCT00820885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which teduglutide is the first listed.
NCT00820885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820885 about?
NCT00820885 is a clinical study titled "A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide". The primary objective of the study was to study the safety and tolerability of teduglutide following a once or possibly twice daily subcutaneous injection for eight consecutive days in healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide following a once or possib...
What is the current status of trial NCT00820885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2006-09-06. Estimated completion is 2007-04-23.
What interventions are being tested in trial NCT00820885?
The interventions under investigation include: teduglutide (DRUG), tedguglutide (DRUG).
Who is sponsoring clinical trial NCT00820885?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.